Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA)

被引：0
|
作者：
Santini, Valeria [1 ]
Fenaux, Pierre [2 ]
Mufti, Ghularn J. [3 ]
Hellstrom-Lindberg, Eva [4 ]
Silverman, Lewis B. [5 ]
List, Alan [6 ]
Gore, Steven D. [7 ]
Seymour, John F. [8 ]
Backstrom, Jay [9 ]
McKenzie, David [9 ]
Beach, C. L. [9 ]
机构：
[1] Azienda Osped Careggi, Florence, Italy
[2] Univ Paris 13, Hop Avicenne, AP HP, Hematol Clin, Bobigny, France
[3] Kings Coll London, Dept Haematol Med, London, England
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[7] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[8] Peter MacCallum Canc Inst, Dept Haematol, Melbourne, Vic, Australia
[9] Celgene, Overland Pk, KS USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：583 / 584
页数：2
相关论文
共 50 条
  • [31] A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Daver, Naval
    Jabbour, Elias
    Jain, Nitin
    Cortes, Jorge E.
    Estrov, Zeev
    Borthakur, Gautam
    Dong, Xiao Q.
    Kumar, Veeral J.
    Kantarjian, Hagop M.
    BLOOD, 2013, 122 (21)
  • [32] Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion independence.
    Zeidan, Amer Methqal
    Schuster, Michael
    Joris, Magalie
    Krauter, Jurgen
    Maertens, Johan
    Gyan, Emmanuel
    Kovacsovics, Tibor
    Verma, Amit
    Vyas, Paresh
    Wang, Eunice S.
    Ma, Wendy
    Zeremski, Mirjana
    Kudla, Art
    Chan, Geoffrey
    Sekeres, Mikkael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] EFFECT OF AZACITIDINE (AZA) vs LOW-DOSE ARA-C (LDAC) ON OVERALL SURVIVAL (OS), HEMATOLOGIC RESPONSE, TRANSFUSION INDEPENDENCE, AND SAFETY IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Fenaux, P.
    Gattermann, N.
    Seymour, J.
    Hellstrom-Lindberg, E.
    Mufti, G. J.
    Duehrsen, U.
    Gore, S.
    Ramos, F.
    Beyne-Rauzy, O.
    Dombret, H.
    List, A.
    McKenzie, D.
    Backstrom, J.
    Allen, A.
    Beach, C. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 90 - 90
  • [34] Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations
    Santini, Valeria
    Prebet, Thomas
    Fenaux, Pierre
    Gattermann, Norbert
    Nilsson, Lars
    Pfeilstoeker, Michael
    Vyas, Paresh
    List, Alan F.
    LEUKEMIA RESEARCH, 2014, 38 (12) : 1381 - 1391
  • [35] Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naive & Relapsed (Rel)/Refractory (Ref) Patients
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Atallah, Ehab L.
    Rajeh, M. Nabeel
    Shammo, Jamile M.
    Griffiths, Elizabeth A.
    Khaled, Samer K.
    Dakhil, Shaker R.
    Young, David E.
    Odchimar-Reissig, Rosalie
    Pemmaraju, Naveen
    Alvarado, Yesid
    Ohanian, Maro N.
    John, Rosmy B.
    Zbyszewski, Patrick S.
    Maniar, Manoj
    Petrone, Michael E.
    Fruchtman, Steven M.
    Silverman, Lewis R.
    BLOOD, 2018, 132
  • [36] Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS
    Cherait, Amina
    Braun, Thorsten
    Bouabdallah, Krimo
    Caillot, Denis
    Guerci, Agnes
    Raffoux, Emmanuel
    Marolleau, Jean Pierre
    Pautas, Cecile
    Banos, Anne
    Himberlin, Chantal
    Taksin, Anne Laure
    Pigneux, Arnaud
    Thomas, Xavier
    Vey, Norbert
    Chevret, Sylvie
    Dombret, Herve
    Chermat, Fatiha
    Ades, Lionel
    Gardin, Claude
    Fenaux, Pierre
    BLOOD, 2020, 136
  • [37] Model-based analysis to support dose selection of pevonedistat (PEV) combined with azacitidine (AZA) in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).
    Zhou, Xiaofei
    Mould, Diane R.
    Zhao, Dan
    Sekeres, Mikkael A.
    Ades, Lionel
    Swords, Ronan T.
    Handa, Hiroshi
    Fram, Robert J.
    Faller, Douglas V.
    Tsukurov, Olga
    Gupta, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    List, Alan F.
    Cuthbertson, David
    Paquette, Ronald
    Latham, Deborah
    Afable, Manual
    Paulic, Katarina
    Loughran, Thomas P., Jr.
    Maciejewski, Jaroslaw P.
    BLOOD, 2008, 112 (11) : 88 - 89
  • [39] Rates of infection and bleeding are not increased in patients with myelodysplastic syndromes (MDS) treated with azacitidine compared with supportive care.
    Silverman, LR
    McKenzie, DR
    Peterson, BL
    Odchimar-Reissig, R
    Hinkle, R
    Backstrom, JT
    Larson, RA
    BLOOD, 2005, 106 (11) : 709A - 709A
  • [40] Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS)
    Chen, James
    Johnson, Lisa
    McKenna, Kelly
    Choi, Timothy
    Duan, Jiaqi
    Feng, Dongdong
    Tsai, Jonathan
    Garcia-Martin, Natalia
    Sompalli, Kavitha
    Maute, Roy
    Vyas, Paresh
    Majeti, Ravindra
    Takimoto, Chris
    Liu, Jie
    Ramsingh, Giridharan
    Chao, Mark
    Volkmer, Jens-Peter
    Weissman, Irving
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S317 - S318
12345